| Literature DB >> 32915805 |
Orhun C Taskin1, Olca Basturk2, Michelle D Reid3, Nevra Dursun4, Pelin Bagci5, Burcu Saka6, Serdar Balci3, Bahar Memis7, Enrique Bellolio8, Juan Carlos Araya9, Juan Carlos Roa10, Oscar Tapia10, Hector Losada11, Juan Sarmiento12, Kee-Taek Jang3, Jin-Young Jang13, Burcin Pehlivanoglu14, Mert Erkan15, Volkan Adsay1.
Abstract
BACKGROUND: Different perspectives exist regarding the clinicopathologic characteristics, biology and management of gallbladder polyps. Size is often used as the surrogate evidence of polyp behavior and size of ≥1cm is widely used as cholecystectomy indication. Most studies on this issue are based on the pathologic correlation of polyps clinically selected for resection, whereas, the data regarding the nature of polypoid lesions from pathology perspective -regardless of the cholecystectomy indication- is highly limited.Entities:
Mesh:
Year: 2020 PMID: 32915805 PMCID: PMC7485812 DOI: 10.1371/journal.pone.0237979
Source DB: PubMed Journal: PLoS One ISSN: 1932-6203 Impact factor: 3.240
Fig 1Non-neoplastic polyps: Fibromyoglandular polyp (A), cholesterol polyp (B), inflammatory polyp (C) and polypoid pyloric gland metaplasia (D) (Hematoxylin&eosin, 10x magnification).
Fig 2Neoplastic polyps: Incipient intracholecystic neoplasm (<1 cm by definition) (A), intracholecystic neoplasm (B), polypoid invasive adenocarcinoma (C) and non-neoplastic polyp (in this case, a cholesterol polyp) with low grade dysplasia (Hematoxylin&eosin, 10x magnification) (D).
Fig 3The flowchart summarized inclusion and exclusion criteria.
Clinicopathologic features and size distribution of gallbladder polyps.
| Polyp Types (defined as ≥ 2mm) | n | Mean age years (range) | Sex (F/M) | Mean size ± SD (mm) | Median size (IQR) (mm) | ≥1 cm | ≥2 cm | |||
|---|---|---|---|---|---|---|---|---|---|---|
| 166 | 46 (21–76) | 2.4 | 3.9 ± 2.4 | 3 (2) | 6 (4%) | 17 (4% of all NNPs) | 0 | 1 (0.2% of all NNPs) | ||
| 196 | 55 (23–93) | 4.4 | 4.2 ± 2 | 4 (2) | 9 (5%) | 0 | ||||
| 41 | 55 (24–77) | 3 | 3.3 ± 1.4 | 3 (2) | 0 | 0 | ||||
| 17 | 59 (38–85) | 1.8 | 6 ± 4.5 | 6 (4) | 2 (12%) | 1 (6%) | ||||
| 120 | 61 (20–94) | 2 | 26.3 | 22 (20) | 120 (by definition) | 155 (69.5% of all NPs) | 73 (61%) | 93 (41% of all NPs) | ||
| 44 | 59 (36–83) | 6.4 | 4.1 | 3 (2) | 0 (by definition) | 0 (by definition) | ||||
| 26 | 71 (48–88) | 7.3 | 28 | 27 (17.25) | 25 (96%) | 18 (69%) | ||||
| 33 | 57 (37–83) | 2 | 8 | 5 (7) | 10 (30%) | 2 (6%) | ||||
NP: Neoplastic polyp.
NNP: Non-neoplastic polyp.
Distribution of cases based on 10-mm size cut-off.
| Size <10 mm (n) | Size ≥10 mm (n) | Total (n) | |
|---|---|---|---|
| 403 (96% of all NNPs) (63% of all polyps) | 17(4% of all NNPs)(3% of all polyps) | 420 | |
| 68 (30% of all NPs) (10% of all polyps) | 155(70% of all NPs)(24% of all polyps) | 223 | |
| 471 (85% NNP, 15% NP) | 172 (90% NP, 10% NNP) | 643 |
Fig 4The ROC analysis has revealed a cut-off of 9 mm, with AUC = 0.854 [0.818–0.889, 95% CI].
At this threshold, the sensitivity was 69.5% and specificity was 95.9%.
Sensitivity, specificity, positive and negative predictive values of different cut-off points.
| Criterion | Sensitivity (%) (95% Cl) | Specificity (%) (95% Cl) | Positive Predictive Value (95% Cl) | Negative Predictive Value (95% Cl) |
|---|---|---|---|---|
| >5 mm | 74.4 (68.2 - 80) | 83.9 (80.1 – 87.4) | 71.2 (65 – 77) | 86 (82.3 – 89.2) |
| > 9 mm | 69.5 (63–75.5) | 95.9 (93.6–97.6) | 90.1 (84.6–94.1) | 85.5 (82–88.6) |
| >10 mm | 66.8 (60.2 - 73) | 97.8 (96 - 99) | 94.3 (89.5 – 97.4) | 84.7 (81.2 – 87.8) |
| >15 mm | 49.7 (43 – 56.5) | 99.2 (97.9 – 99.9) | 97.4 (92.5 – 99.5) | 78.7 (75 – 82.2) |
| >20 mm | 37.6 (31.3 – 44.4) | 100 (99.1 - 100) | 100 (95.7 – 100) | 75 (71.2 – 78.6) |
| >25 mm | 29.6 (23.7 – 36.1) | 100 (99.1 - 100) | 100 (94.6 – 100) | 72.7 (68.9 – 76.3) |